Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

Phase II data from study of GAMMAGARD-treated patients announced at the

American Academy of Neurology annual meeting

CHICAGO, April 17 /PRNewswire-FirstCall/ -- New York-Presbyterian Hospital/Weill Cornell Medical Center and Baxter International Inc. (NYSE: BAX) announced results of a six-month, placebo-controlled Phase II study of 24 patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)] for the treatment of mild-to-moderate Alzheimer's disease today at the American Academy of Neurology (AAN) annual meeting in Chicago. The study met the primary endpoint criteria favoring GAMMAGARD LIQUID and GAMMAGARD S/D over placebo on measures of cognitive function and global impression of change, which are common measures of outcome in Alzheimer's disease clinical trials. The study also met secondary endpoints that measured changes in beta-amyloid and anti-amyloid antibody levels in blood and cerebrospinal fluid. Results show findings indicative of potential efficacy and tolerability. Key findings throughout six months included: measurements of clinical outcome, behavioral outcome and cognitive performance in Alzheimer's patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID compared to placebo. Twelve-to-18 month data will be available later this year.

Secondary endpoint results suggest that levels of antibodies against beta-amyloid were observed to have increased in the blood and cerebrospinal fluid of patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID, while the levels of beta-amyloid increased in the blood. Beta-amyloid is a substance thought to contribute to the degeneration of the brain in Alzheimer's disease. Clearing this substance from the central nervous system, therefore is hypothesized to help remove or reduce the building blocks of Alzheimer's.

The primary and secondary endpoint data were reported by the lead researcher for the trial, Dr. Norman Relkin, director of the Memory
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... --  Hospira, Inc. (NYSE: HSP ), ... leading provider of injectable drugs and infusion technologies, ... biosimilarity of its proposed biosimilar, Epoetin Hospira, with ... approved name of RETACRIT™, compared to the reference ... were presented at the National Kidney Foundation (NKF) ...
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
(Date:3/27/2015)... 2015  WebMD Health Corp. (NASDAQ: ... information, today announced an exclusive White House ... Plan for Combating Antibiotic-Resistant Bacteria . During ... and importance of addressing antibiotic-resistant bacteria and ... The WebMD interview, available online ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Schering-Plough,Corporation (NYSE: SGP ) and The ... of Baltimore today announced results of the ... Eptifibatide to,Arrest the Reactivity of Platelets) study, ... IIIa inhibitor, significantly inhibited,platelet aggregation when added ...
... Immtech Pharmaceuticals,Inc. (Amex: IMM ) today ... a,scientific consortium led by the University of North ... The Bill & Melinda Gates Foundation,(the "Gates Foundation"), ... and leishmania. This grant is part of the ...
Cached Medicine Technology:Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 2Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 3Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 4Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 5Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 2Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 3
(Date:3/29/2015)... (PRWEB) March 29, 2015 North American ... PT Online Continuing Education Courses . ... hours of CME - TPTA, approval # 56399TX      ... evaluation of the shoulder complex - 10.5 hours - ... #56400TX , Examination and Treatment of the SI Joint ...
(Date:3/28/2015)... Bellingham, WA (PRWEB) March 28, 2015 ... for athletes, recently announced the release of their new natural ... ounce and 3 ounce packages. Both options come with ... be purchased at RocketPure.com or on Amazon. Click ... product description states that the natural sunscreen is made with ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni ... tumble into the stomach, ready to break down your ... these acids run amok, triggering a burning sensation in ... than 60 million Americans have heartburn at least once ... and how it can be stopped. , Heartburn or ...
(Date:3/28/2015)... New York, New York (PRWEB) March 28, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. ... multidistrict litigation underway in U.S. District Court, Southern ... Jeffrey S. Grand, is serving on the Plaintiffs’ ... March 24th, the Court has granted certain defendants ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4
... Earnings in Line with GuidanceHAYWARD, Calif., May 4 Ultra ... developer and supplier of critical subsystems for the semiconductor capital ... its financial results for the first quarter ended April 3, ... $22.4 million, a decrease of 52% from the fourth quarter ...
... Rep. Brian Bosma as Master of Ceremonies, and Miss Indiana ... Better Hearing and Speech Month , Hear Indiana will hold ... Peyton Manning Children,s Hospital at St. Vincent. Please join us ... of Newborn Hearing Screening in Indiana. Same-day registration and packet ...
... Every summer, valley businesses shed their business attire in ... all in the spirit of raising money for United Cerebral ... with disabilities. This year, the theme is Camp Casual ... June 17th though businesses can choose to hold their event ...
... Study suggests they,re less likely to separate reality from fiction ... watched adult-themed movies and television shows as children become sexually ... Hospital Boston study finds. , It included 754 participants who ... they were aged 12 to 18. The earlier in their ...
... PITTSBURGH, May 4 Health Monitoring Systems (HMS) is ... healthcare information technology arena: Community Health Surveillance. HMS is ... they work to monitor the H1NI Flu (Swine Flu). ... and characterize the outbreak of H1N1 since the first ...
... of Online, Educational Resources Aims to Empower Children With ... , NEW YORK, May 4 ... across the country, BrainPOP -- ... 3 and up -- has launched a new, free ...
Cached Medicine News:Health News:Ultra Clean Reports Q1 '09 Financial Results 2Health News:Ultra Clean Reports Q1 '09 Financial Results 3Health News:Ultra Clean Reports Q1 '09 Financial Results 4Health News:Ultra Clean Reports Q1 '09 Financial Results 5Health News:Ultra Clean Reports Q1 '09 Financial Results 6Health News:Hear Indiana holds 6th Annual Talk Walk Run at Fort Harrison State Park to Celebrate Deaf Children Who Listen and Speak 2Health News:Hear Indiana holds 6th Annual Talk Walk Run at Fort Harrison State Park to Celebrate Deaf Children Who Listen and Speak 3Health News:Valley Businesses Shedding Their Suits to Go Casual for a Cause 2Health News:Viewing Adult-Themed TV Tied to Earlier Sex for Teens 2Health News:Pittsburgh Life Sciences Company Using Community Health Surveillance Platform to Track H1N1 Flu (Swine Flu) 2Health News:Free New Content From BrainPOP Helps Explain Swine Flu to Kids 2
... The Venus-i™ Laser System is a new, ... system with applications in dermatology, cosmetic and ... An ideal laser for skin resurfacing, it ... powerful, Erbium:YAG lasers on the market. It ...
... biolitecs sophisticated Ceralas D15/810 diode laser is ... ideal for many soft tissue applications. With ... D15/810 features a flexible fiber optic delivery ... irrigated or dry environments alike.,Compact and portable, ...
... D 980 nm diode laser provides controlled ... for most surgical procedures. Unlike other ... without collateral tissue damage or charring. ... instantly and seals small blood vessels ...
... The TonoPach is a device intended for ... IOP remains the single most important metric ... However, as discovered in a large, ... study published in mid-2002, the patients central ...
Medicine Products: